5 completed, 1 recruiting. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 5, Recruiting 1 |
| Phase 2 | 3 | Completed 3 |
Follow IVA: new trials by email Literature Review of IVA trials Research Report on IVA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis VX-581, Placebo, D-IVA - Cystic Fibrosis | Phase 1 | Recruiting | Vertex Pharmaceuticals Incorporated | 152 | 2025-12-09 | 2026-10-19 |
| A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) VX-522 mRNA therapy, IVA - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 26 | 2023-02-27 | 2026-10-09 |
| Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis Placebo (matched to VX-121 suspension), VX-121 (Suspension), TEZ/IVA - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 115 | 2018-03-20 | 2022-07-14 |
| A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis IVA, TEZ/IVA, VX-445 - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 225 | 2017-01-23 | 2022-01-18 |
| A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis VX-659, Tezacaftor, Ivacaftor - Cystic Fibrosis | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 163 | 2016-11-01 | 2017-09-05 |
| A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects VX-440, TEZ, IVA - Cystic Fibrosis | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 16 | 2016-07-20 | 2018-04-03 |
Cystic Fibrosis (6)
Vertex Pharmaceuticals Incorporated (6)
United Kingdom (4) · United States (3) · Australia (2) · Belgium (2) · Netherlands (2) · Canada (1) · Germany (1) · Sweden (1)
PMID 33331662, PMID 37983082, PMID 30334692, PMID 30334693
2016 (2), 2017 (1), 2018 (1), 2023 (1)